MDM2, MDMX and p53 in oncogenesis and cancer therapy

Cited by (998)

Items 701–800 of 998

1. Amino acid-based biomaterials for modulation of cell behaviors: from mechanisms to biomedical applications
   Mingyue Liu, Jinjin Chen, Hongjie Li, Yulong Ma, Qingyang Xiao, Jianxun Ding, Jinghong Li, Xuesi Chen · 2026 · Chemical Society Reviews
2. MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells
   Renier C. Heijkants, Amina F.A.S. Teunisse, Daniëlle de Jong, Kseniya Glinkina, Hailiang Mei, Szymon M. Kiełbasa, Károly Szuhai, Aart G. Jochemsen · 2022 · Cancers
3. Circular RNA circNIPBL regulates TP53-H179R mutations in NNK-induced bronchial epithelial carcinogenesis
   Yufei Liu, Shusen Fang, Tianshu Lin, Wei Chen, Yushan Chen, Ye Wang, Xietian Xiao, Hengfa Zheng, Lulu Liu, Jiayu Zhou et al. · 2024 · Environment International
4. Insights into the Interaction Mechanisms of Peptide and Non-Peptide Inhibitors with MDM2 Using Gaussian-Accelerated Molecular Dynamics Simulations and Deep Learning
   Wanchun Yang, Jian Wang, Lu Zhao, Jianzhong Chen · 2024 · Molecules
5. Design, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity In Vivo
   Lei Xu, Xin Fan, Yi He, Xuefeng Xia, Jinqiang Zhang · 2024 · Journal of Medicinal Chemistry
6. Ubiquitin ligase A20 regulates p53 protein in human colon epithelial cells
   Jing Liu, Shaobo Yang, Zhiqiang Wang, Xiao Chen, Ziqi Zhang · 2013 · Journal of Biomedical Science
7. Cerebellum Development and Tumorigenesis: A p53-Centric Perspective
   Nicolas J. Barthelery, James J. Manfredi · 2016 · Trends in Molecular Medicine
8. Comprehensive characterization of genes associated with the TP53 signal transduction pathway in various tumors
   Shumpei Ohnami, Keiichi Ohshima, Takeshi Nagashima, Kenichi Urakami, Yuji Shimoda, Junko Saito, Akane Naruoka, Keiichi Hatakeyama, Tohru Mochizuki, Masakuni Serizawa et al. · 2017 · Molecular and Cellular Biochemistry
9. Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α
   Robert D. Kendig, Fumitake Kai, Elizabeth A. Fry, Kazushi Inoue · 2017 · Cancer Investigation
10. Exploiting Protein Corona around Gold Nanoparticles Conjugated to p53 Activating Peptides To Increase the Level of Stable p53 Proteins in Cells
    Kian Ping Chan, Sheng‐Hao Chao, James Chen Yong Kah · 2019 · Bioconjugate Chemistry
11. LINC01116 promotes the proliferation and invasion of glioma by regulating the microRNA‑744‑5p‑MDM2‑p53 axis
    Li Jiang, Chao Cheng, Wei Ji, Hao Wang, Quan Du, Xiao‐Qiao Dong, Junfei Shao, Wenhua Yu · 2021 · Molecular Medicine Reports
12. p53 Ubiquitination Comediated by HUWE1 and TRAF6 Contributes to White Spot Syndrome Virus Infection in Crustacean
    Yi Gong, Tongtong Kong, Jude Juventus Aweya, Hongyu Ma, Yueling Zhang, Shengkang Li · 2022 · Journal of Virology
13. MDM2–MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance
    Salvatore Cannistraro, Ilaria Moscetti, Emanuela Teveroni, Fabiola Moretti, Anna Rita Bizzarri · 2016 · International Journal of Nanomedicine
14. Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex
    Giovanna Carrà, Sabrina Crivellaro, Riccardo Taulli, Angelo Guerrasio, Giuseppe Nicola Saglio, Alessandro Morotti · 2016 · International Journal of Molecular Sciences
15. Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells
    Sanjay Kumar, Andrea M. Brown, Paul Bernard Tchounwou · 2018 · Oncotarget
16. Drug Design of “Undruggable” Targets
    Jie Wang, Shiliang Li, Honglin Li · 2019 · Chinese Journal of Chemistry
17. MTA1 Promotes Hepatocellular Carcinoma Progression by Downregulation of DNA-PK-Mediated H1.2T146 Phosphorylation
    Yuhui Li, Ming Zhong, Hong-Liang Zang, Xiao-Feng Tian · 2020 · Frontiers in Oncology · Retracted
18. Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
    Xiuzhen Zhang, Tong Meng, Shuaishuai Cui, Ling Feng, Dongwu Liu, Qiuxiang Pang, Ping Wang · 2021 · Frontiers in Oncology
19. Direct Interaction of miRNA and circRNA with the Oncosuppressor p53: An Intriguing Perspective in Cancer Research
    Anna Rita Bizzarri, Salvatore Cannistraro · 2021 · Cancers
20. MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
    Mitsuaki Hirose, Kenji Yamato, Shinji Endo, Rie Saito, Takunori Ueno, Sachiko Hirai, Hideo Suzuki, Masato Abei, Yukikazu Natori, Ichinosuke Hyodo · 2014 · Oncoscience
21. MDM2/MDMX: Master negative regulators for p53 and RB
    Linshan Hu, Haibo Zhang, Johann S. Bergholz, Shengnan Sun, Zhi‐Xiong Jim Xiao · 2016 · Molecular & Cellular Oncology
22. Understanding the interaction of 14‐3‐3 proteins with h DMX and h DM2: a structural and biophysical study
    Sonja Srdanović, M. Wolter, Chi H. Trinh, Christian Ottmann, Stuart L. Warriner, Andrew John Wilson · 2022 · FEBS Journal
23. miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia
    Han Zhong Pei, Zhiyong Peng, Xiaomei Zhuang, Xiaobo Wang, Bo Lü, Yao Guo, Yuming Zhao, Dengyang Zhang, Yunjun Xiao, Tianshun Gao et al. · 2023 · Cell Death Discovery
24. Expanding the ubiquitin code in pancreatic cancer
    Wenyan Yang, Shiqun Wang, Shengqiang Tong, Weidong Zhang, Jiang‐Jiang Qin · 2023 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
25. SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy
    Xiangyuan Luo, Zerui Zhang, Siwen Li, Yijun Wang, Mengyu Sun, Dian Xing Hu, Junqing Jiang, Yufei Wang, Xiaoyu Ji, Xiaoping Chen et al. · 2023 · International Immunopharmacology
26. Bidirectional linkage of DNA barcodes for the multiplexed mapping of higher-order protein interactions in cells
    Yu Liu, Noah R. Sundah, Nicholas R. Y. Ho, Wan Xiang Shen, Yun Xu, Auginia Natalia, Zhonglang Yu, Ju Ee Seet, Ching Wan Chan, Tze Ping Loh et al. · 2024 · Nature Biomedical Engineering
27. MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC
    Jiaxin Liu, Lingyun Wei, Qing Miao, Sutong Zhan, Peilin Chen, Wei Liu, Liang Cao, Dong Wang, Hongbing Liu, Jie Yin et al. · 2024 · Journal of Experimental & Clinical Cancer Research
28. Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target
    Fabio Sias, Stefano Zoroddu, Rossana Migheli, Luigi Bagella · 2025 · International Journal of Molecular Sciences
29. MDM2 SNP309 variation increases cervical cancer risk among Asians
    Xianlu Zhuo, Jie Ren, Dairong Li, Yongzhong Wu, Qi Zhou · 2014 · Tumor Biology
30. A Systematic Review and Meta-Analysis of Three Gene Variants Association with Risk of Prostate Cancer: An Update.
    Yu Chen, Huan Zhong, Jianguo Gao, Jianer Tang, Rongjiang Wang · 2015 · Urology journal./Urology jornal.
31. RETRACTED: Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777
    Pichaya Thanindratarn, Xiaoyang Li, Dylan C. Dean, Scott D. Nelson, Francis John Hornicek, Zhenfeng Duan · 2019 · Journal of Orthopaedic Research® · Retracted
32. Genomic and Transcriptomic Characterization of Canine Osteosarcoma Cell Lines: A Valuable Resource in Translational Medicine
    Cecilia Gola, Diana Giannuzzi, Andrea Rinaldi, Selina Iussich, Paola Modesto, Emanuela Maria Morello, Paolo Buracco, Luca Aresu, Raffaella De Maria · 2021 · Frontiers in Veterinary Science
33. The ion channel TRPM7 regulates zinc-depletion-induced MDMX degradation
    Herui Wang, Bin Li, Kulsum Asha, Ryan L. Pangilinan, Asha Thuraisamy, Harman Chopra, Susumu Rokudai, Yong Yu, Carol L. Prives, Yan Yu Zhu · 2021 · Journal of Biological Chemistry
34. Hesperidin Inhibits the p53-MDMXInteraction-Induced Apoptosis of Non-Small-Cell Lung Cancer and Enhances the Antitumor Effect of Carboplatin
    Yu Feng, Hongjie Huo, Qiong Tang · 2022 · Journal of Oncology
35. Mdm2 and MdmX Involvement in Human Cancer
    Steven J. Berberich · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
36. The Cell Cycle Regulator CCDC6 Is a Key Target of RNA-Binding Protein EWS
    Sujitha Duggimpudi, Erik Larsson, Schafiq Nabhani, Arndt Borkhardt, Jessica I. Hoell · 2015 · PLoS ONE
37. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma
    Xiaoge Gao, Meng‐Xue Wei, Wenhua Shan, Qian Liu, Jian Hua Gao, Yong U. Liu, Songlei Zhu, Hong Yao · 2019 · Pharmacological Research
38. Silencing of zinc finger protein 703 inhibits medullary thyroid carcinoma cell proliferation in�vitro and in�vivo
    Xiaolin Yang, Geling Liu, Weijuan Li, Lu‐Yang Zang, Ding Li, Qianqian Wang, Fang Yu, Xiuxiu Xiang · 2019 · Oncology Letters
39. Overexpression of negative regulator of ubiquitin-like proteins 1 (NUB1) inhibits proliferation and invasion of gastric cancer cells through upregulation of p27Kip1 and inhibition of epithelial-mesenchymal transition
    Dongdong Zhang, Pei Wu, Zhe Zhang, Wen An, Chao Zhang, Siwei Pan, Yuen Tan, Huimian Xu · 2020 · Pathology - Research and Practice
40. MDM2 promotes the proliferation and inhibits the apoptosis of pituitary adenoma cells by directly interacting with p53
    Yibiao Wang, Jiannong Zhao, Chaocai Zhang, Pengcheng Wang, Chuixue Huang, Hao Fan Peng · 2020 · Endokrynologia Polska
41. Genomic profiling of the transcription factor Zfp148 and its impact on the p53 pathway
    Zhiyuan V. Zou, Nadia Gul, Markus Lindberg, Abdulmalik A. Bokhari, Ella Äng Eklund, Viktor Garellick, Angana A. H. Patel, Jozefina J. Dzanan, Ben Oliver Titmuss, Kristell Le Gal et al. · 2020 · Scientific Reports
42. The prognostic value of USP7 and p53 in advanced hypopharyngeal carcinoma
    Ji Sun, Lan Lin, Jiahao Zhang, Chunyan Hu, Jie Wang · 2021 · Annals of Diagnostic Pathology
43. Model-based translation of DNA damage signaling dynamics across cell types
    Muriel M. Heldring, Lukas S. Wijaya, Marije Niemeijer, Huan Yang, T Lakhal, Sylvia E. Le Dévédec, Bob van de Water, Joost B. Beltman · 2022 · PLoS Computational Biology
44. Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis
    Bo Wu, Dan Guo, Ying Qiang Guo · 2013 · Tumor Biology
45. Activation of p53/miR‐34a Tumor Suppressor Axis by Chinese Herbal Formula JP‐1 in A549 Lung Adenocarcinoma Cells
    Chih‐Jung Yao, Jyh‐Ming Chow, Pei-Chun Lin, Tsai-Shu Hu, Hui-Ching Kuo, Jhy-Shrian Huang, Kuan‐Jen Bai, Gi‐Ming Lai · 2016 · Evidence-based Complementary and Alternative Medicine
46. Genomics of Immunotherapy-Associated Hyperprogressors—Letter
    Andrea Forschner, Heike Niessner, Yvonne Möller, Peter Horak, Martina Fröhlich, Gregor Warsow, Albrecht Stenzinger, Stefan Fröhling, Hanno Glimm, Bernhard Daniel Klumpp et al. · 2017 · Clinical Cancer Research
47. The circular RNA hsa_circ_0001394 promotes hepatocellular carcinoma progression by targeting the miR-527/UBE2A axis
    Yan Yu, Yu Nie, Chun Peng, Fuchen Xing, Saiguang Ji, Hong Liu, Chuandong Zhu · 2022 · Cell Death Discovery
48. RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells
    Lena Hölzen, Jan Mitschke, Claudia Schönichen, Maria Elena Hess, Sophia Ehrenfeld, Melanie Boerries, Cornelius Miething, Tilman Brummer, Thomas Reinheckel · 2022 · Theranostics
49. CircCCDC66: Emerging roles and potential clinical values in malignant tumors
    Xiaoxiao Wang, Chao Zhang, Huangqin Song, Junlong Yuan, Lei Zhang, Jiefeng He · 2023 · Frontiers in Oncology
50. Expression of miRNA from spent pre-implantation embryos culture media
    Claudia Omes, A Conti, Laura Benedetti, Veronica Tomasoni, Davide De Marchi, Rossella Elena Nappi, Maria Gabriella Cusella De Angelis, Gabriele Ceccarelli · 2024 · Reproductive Biology
51. Targeting PD-1 post-translational modifications for improving cancer immunotherapy
    Jie Shi, Chuan He, Li Chen, Xixin Xing, Wenyi Wei, Jinfang Zhang · 2025 · Cell Insight
52. Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research
    Meichen Pan, Zhongliang Fu, Hongwei Hou, Chunrong Yang, Jinghong Li · 2025 · Small Methods
53. Autoantibody to MDM2: A Potential Serological Marker of Systemic Lupus Erythematosus
    Yuan Liu, Liping Dai, Weihong Liu, Guixiu Shi, Jianying Zhang · 2015 · Journal of Immunology Research
54. Mechanisms involved in p53 downregulation by leptin in trophoblastic cells
    Ayelén Rayen Toro, Antonio Pérez‐Pérez, Isabel Corrales-Gutiérrez, Víctor Sánchez‐Margalet, Cecilia Laura Varone · 2015 · Placenta
55. Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment
    Joana Almeida, Inês N. R. Mota, Jan Skoda, Emília Sousa, Honorina M. Cidade, Lucília Saraiva · 2022 · Cancers
56. State of the Art of Pharmacological Activators of p53 in Ocular Malignancies
    Fabio Casciano, Enrico Zauli, Massimo Busin, Lorenzo Caruso, Saleh Al-Mesfer, Samar A. Al-Swailem, Giorgio Zauli, Angeli Christy Yu · 2023 · Cancers
57. A Cell-Permeable Fusion Protein Based on Clostridium botulinum C2 Toxin for Delivery of p53 Tumorsuppressor into Cancer Cells
    Jörg Fahrer, Johannes Rausch, Holger Barth · 2013 · PLoS ONE
58. Cell Cycle Regulation via the p53, PTEN, and BRCA1 Tumor Suppressors
    Akari Minami, Toshiyuki Murai, Atsuko Nakanishi, Yasuko Kitagishi, Mayuko Ichimura‐Shimizu, Satoru Matsuda · 2016 · InTech eBooks
59. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
    Liangshun You, Hui Liu, Jian Huang, Wanzhuo Xie, Jueying Wei, Xiujin Ye, Wenbin Qian · 2016 · Oncotarget
60. Haemagglutinin-neuraminidase from HPIV3 mediates human NK regulation of T cell proliferation via NKp44 and NKp46
    S. McQuaid, Sinéad T. Loughran, Patrick Power, Paula T. Maguire, Dermot Walls, Maria Grazia Cusi, Claes Örvell, PATRICIA A. JOHNSON · 2018 · Journal of General Virology
61. Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function
    S -Y Lau, Jia Wei Siau, Radoslaw Mikolaj Sobota, C -I Wang, Pingyu Zhong, David Philip Lane, Farid John Ghadessy · 2018 · Protein Engineering Design and Selection
62. Inverse association between MDM2 and HUWE1 protein expression levels in human breast cancer and liposarcoma.
    Kaleigh Canfield, Wendy A. Wells, Joseph Geradts, William B. Kinlaw, Chao Cheng, Manabu Kurokawa · 2016 · PubMed
63. Identification of an Autophagy-Related Signature Predicting Overall Survival for Papillary Thyroid Carcinoma
    Gang Hu, Hong-Fang Feng, Hui Zhan · 2020 · Dose-Response
64. Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC
    Rossella Pellegrino, Abhishek Thavamani, Diego Francesco Calvisi, Jan Budczies, Ariane Neumann, Robert Geffers, Jasmin Kroemer, Damaris Greule, Peter Schirmacher, Alfred Nordheim et al. · 2021 · Cancers
65. Investigation of the inhibitory mechanism of apomorphine against MDM2–p53 interaction
    Ishiba, Hiroyuki, Noguchi, Taro, Shu, Keitou, Ohno, Hiroaki, Honda, Kaori, Kondoh, Yasumitsu, Osada, Hiroyuki, Fujii, Nobutaka, Oishi, Shinya · 2017 · Bioorganic & Medicinal Chemistry Letters
66. Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges
    Helen O. Ajufo, Julian A. Waksal, John O Mascarenhas, Raajit K. Rampal · 2023 · Therapeutic Advances in Hematology
67. Death-associated protein kinase 1 phosphorylates MDM2 and inhibits its protein stability and function
    Mi Zhang, Xindong Shui, Xiaoqing Zheng, Jong Eun Lee, Yingxue Mei, Ruomeng Li, Yuan Tian, Xiuzhi Zheng, Quling Wang, Long Wang et al. · 2023 · Archives of Pharmacal Research
68. The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer
    Ze Rong, Kaifeng Zheng, Jun Chen, Xiaofeng Jin · 2024 · Journal of Cancer Research and Clinical Oncology
69. Targeting MDM2-p53 interaction in Glioblastoma: Transcriptomic analysis and Peptide-Based inhibition strategy
    Manman Han, Mohibullah Kakar, Wei Li, Imran Iqbal, Xiaolin Hu, Yiting Liu, Qing Tang, Lizhu Sun, Yasmeen Shakir, Tiantian Liu · 2024 · Bioorganic Chemistry
70. USP38 functions as an oncoprotein by downregulating the p53 pathway through deubiquitination and stabilization of MDM2
    Shanyu Zhao, Xiaoli Liu, Rongkui Luo, Zitao Jian, Chen Xu, Yingyong Hou, Xiuping Liu, Pingzhao Zhang · 2025 · Cell Death and Differentiation
71. Key genes altered in glioblastoma based on bioinformatics (Review)
    Marcelino Al Ghafari, Nour El Jaafari, Mariam Mouallem, Tala Maassarani, Mirvat El‐Sibai, Ralph Joseph Abi‐Habib · 2025 · Oncology Letters
72. Cellular senescence in kidney diseases
    Xiaojie Wang, Yujia Li, Qingqing Chu, Hang Lv, Jing Li, Fan Yi · 2025 · Chinese Medical Journal
73. MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials
    Francesco Russano, Mattia Sturlese, Luigi Dall’Olmo, Francesco Callegarin, Davide Brugnolo, Paolo Del Fiore, Valeria Patti, A Henoch-Schönlein Purpura, Stefano Moro, Marco Rastrelli et al. · 2025 · International Journal of Molecular Sciences
74. Decoding the Pathophysiology and the Genetics of Multiple Myeloma to Identify New Therapeutic Targets
    Panisinee Lawasut, Richard W.J. Groen, Eugen Dhimolea, Paul Gerard Guy Richardson, Kenneth Carl Anderson, Constantine S. Mitsiades · 2013 · Seminars in Oncology
75. Dephosphorylation of p53 Ser 392 Enhances Trimethylation of Histone H3 Lys 9 via SUV39h1 Stabilization in CK2 Downregulation-Mediated Senescence.
    Jeong‐Woo Park, Young‐Seuk Bae · 2019 · PubMed Central
76. Identification of a Structural Determinant for Selective Targeting of HDMX
    Yael Ben‐Nun, Hyuk‐Soo Seo, Edward P. Harvey, Zachary J. Hauseman, Thomas E. Wales, Catherine E. Newman, Ann M. Cathcart, John R. Engen, Sirano Dhe‐Paganon, Loren D. Walensky · 2020 · Structure
77. Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development
    Vítor Hugo Sales da Mota, Fabrício Freire de Melo, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Kádima Nayara Teixeira · 2022 · World Journal of Clinical Oncology
78. The Study of MDM2 rs937283 Variant and Cancer Susceptibility in a Central Chinese Population
    Bifeng Chen, Jingdong Wang, Jieling Wang, Jingli Zhang, Xiuli Gu, Xianhong Feng · 2018 · Technology in Cancer Research & Treatment
79. Cisplatin binds to the MDM2 RING finger domain and inhibits the ubiquitination activity
    Kaiming Cao, Xin Ding, Yaping Sheng, Yu Wang, Yangzhong Liu · 2020 · Chemical Communications
80. The overexpression of SOX2 affects the migration of human teratocarcinoma cell line NT2/D1
    Danijela Drakulić, Jelena Marjanović, Marija Schwirtlich, Jelena Tošić, Aleksandar Krstić, Andrijana Klajn, Milena J. Stevanović · 2015 · Anais da Academia Brasileira de Ciências
81. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells
    Xiaoli Xu, Qichao Bao, Jian-Min Jia, Fang Liu, Xiaoke Guo, Ming-ye Zhang, Jinlian Wei, Mengchen Lu, Lili Xu, Xiaojin Zhang et al. · 2016 · Scientific Reports
82. Design and Synthesis of Disulfide-Rich Peptides with Orthogonal Disulfide Pairing Motifs
    Zirong Huang, Yapei Wu, Huilei Dong, Yibing Zhao, Chuanliu Wu · 2020 · The Journal of Organic Chemistry
83. Changes in the Transcriptome Caused by Mutations in the Ribosomal Protein uS10 Associated with a Predisposition to Colorectal Cancer
    Yueming Tian, Elena S. Babaylova, Alexander V. Gopanenko, Alexey E. Tupikin, Marsel Rasimovich Kabilov, Alexey A. Malygin, Galina G. Karpova · 2022 · International Journal of Molecular Sciences
84. Metformin as a promising therapeutic agent for papillary thyroid cancer: Mechanisms of antitumor and pro-apoptotic activity
    Katarzyna Wincenciuk, Angelika Buczyńska, Adam Jacek Kretowski, Agnieszka Adamska · 2025 · Translational Oncology
85. Unveiling the “Three‐Finger Pharmacophore” Required for p53–MDM2 Inhibition by Saturation‐Transfer Difference (STD) NMR Initial Growth‐Rates Approach
    Jesus Angulo, Sarah A. Goffin, Daivik Gandhi, Mark Searcey, Lesley A. Howell · 2016 · Chemistry - A European Journal
86. The prevalence of HLA‐I LOH in Chinese pan‐cancer patients and genomic features of patients harboring HLA‐I LOH
    Jian Zhao, Xiaoxiong Xiao, Yue Li, Xuan Gao, Xiuqin Zhang, Zeyi Liu, Yuting Yi, Xiaorui Fu, Han Wang, Yanfang Guan et al. · 2021 · Human Mutation
87. Identification of a small-molecule RPL11 mimetic that inhibits tumor growth by targeting MDM2-p53 pathway
    Bing‐Wu Wang, Jian Gao, Zhongjun Zhao, Xuefei Zhong, Hao Cui, Hui Hou, Yanping Zhang, Junnian Zheng, Jiehui Di, Yong Liu · 2022 · Molecular Medicine
88. Long noncoding RNA LINC01088 inhibits esophageal squamous cell carcinoma progression by targeting the NPM1-HDM2-p53 axis
    Fan Liang, Qiuli Luo, Haibo Han, Jianzhi Zhang, Yue Yang, Jinfeng Chen · 2023 · Acta Biochimica et Biophysica Sinica
89. Unleashing the potential of natural biological peptide Macropin: Hydrocarbon stapling for effective breast cancer treatment
    Baobao Chen, Yinghua Li, Haohao Bai, Yajing Ji, Wei Cong, Honggang Hu, Shipeng He · 2023 · Bioorganic Chemistry
90. Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach
    Keting Li, Wenshu Hu, Yingjie Wang, Wenxing Chen, Hongmei Wen, Jian Liu, Wěi Li, Bo Wang · 2023 · Journal of Enzyme Inhibition and Medicinal Chemistry
91. Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance
    Wanxian Chen, Deyi Geng, Jiasheng Chen, Xiaosha Han, Qihu Xie, Genghong Guo, Xuefen Chen, Wancong Zhang, Shijie Tang, Xiaoping Zhong · 2024 · Cancer Cell International
92. Arterial-Lymphatic-Like Endothelial Cells Appear in Hereditary Hemorrhagic Telangiectasia 2 and Contribute to Vascular Leakage and Arteriovenous Malformations
    Yang Yang, Xiuju Wu, Yan G. Zhao, Daoqin Zhang, Li Zhang, Xinjiang Cai, Jaden Ji, Zheng Jing, Kristina I. Boström, Yucheng Yao · 2024 · Circulation
93. Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy
    Mariana Malvicini, Jorge Benjamin Aquino, Guillermo Daniel Mazzolini · 2015 · Current Gene Therapy
94. E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting
    Joseph Y. Ong, Jorge Z. Torres · 2019 · IntechOpen eBooks
95. Acylation of the antimicrobial peptide CAMEL for cancer gene therapy
    Jingjing Song, Panpan Ma, Sujie Huang, Juanli Wang, Huan Xie, Bo Jia, Wei Zhang · 2020 · Drug Delivery
96. Effect of murine double‐minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys
    Yoshiko Kawata, Kazunori Nagasaka, Katsutoshi Oda, Chinami Makii, Makoto Takeuchi, Shinya Oki, Harunori Honjo, Machiko Kojima, Yuko Miyagawa, Ayumi Taguchi et al. · 2020 · Cancer Science
97. Exploration of targets and molecular mechanisms of cinnamaldehyde in overcoming fulvestrant-resistant breast cancer: a bioinformatics study
    Adam Hermawan, Herwandhani Putri, Rohmad Yudi Utomo · 2021 · Network Modeling Analysis in Health Informatics and Bioinformatics
98. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
    Seyed Saeed Pairawan, Argun Akçakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Q. Rizvi, Vijaykumar R. Holla, Jing Wang et al. · 2022 · Scientific Reports
99. USP49-Mediated Histone H2B Deubiquitination Regulates HCT116 Cell Proliferation through MDM2-p53 Axis
    Lei Shi, Xiangyu Shen, Yuan Shen · 2022 · Molecular and Cellular Biology
100. Farnesoid X receptor functions in cervical cancer via the p14ARF-mouse double minute 2-p53 pathway
     Xiaohua Huang, Bin Wang, Huimin Shen, Danmei Huang, Ganggang Shi · 2022 · Molecular Biology Reports